Given several PARP inhibitors approved or with emerging positive data in castrate resistant prostate cancer, how do you decide which one and when to use?   

At this point, it's easy. In the prechemo mCRPC state, the answer is olaparib, but it is expected that rucaparib will be an alternative. In the mCRPC state post chemo, could be either olaparib or rucaparib. The others are not yet approved. We are participating in the trial AMPLITUDE, which is lookin...

The only two approved PARP inhibitors in mCRPC are olaparib and rucaparib. These have different labels (Olaparib has approval for a larger panel of gene mutations and is approved in pre-chemotherapy settings, while rucaparib is approved only for BRCA1, BRCA2, and ATM, and approved in post-chemothera...